헬스케어 관련 감염증 진단 시장 : 제품 및 서비스, 질병 유형, 최종 사용자별 - 세계 예측(2025-2030년)

The Healthcare-associated Infectious Disease Diagnostics Market was valued at USD 4.04 billion in 2023, expected to reach USD 4.37 billion in 2024, and is projected to grow at a CAGR of 8.35%, to USD 7.09 billion by 2030.

Healthcare-associated infectious disease diagnostics refer to the variety of tests and methodologies employed to detect infections contracted in healthcare settings, such as hospitals and outpatient clinics. The necessity of these diagnostics arises from the need to control and manage infections that pose significant risks to patient safety, prolong hospital stays, and increase healthcare costs. The application of diagnostic tools spans various stages, from initial detection and diagnosis to ongoing monitoring and management of infectious diseases. Key end-users include hospitals, diagnostic laboratories, and outpatient healthcare facilities, where rapid and accurate diagnostics are crucial for effective infection control and prevention strategies.

Market insights indicate that the growth of healthcare-associated infectious disease diagnostics is predominantly driven by the increasing prevalence of healthcare-associated infections (HAIs), advancements in diagnostic technologies, and rising awareness of infection control practices. The latest opportunities emerge from the development of rapid diagnostic kits, which shorten the time needed for diagnosis and treatment, and the integration of artificial intelligence and machine learning to enhance diagnostic accuracy and efficiency. Companies can capitalize on these opportunities by investing in R&D for innovative diagnostic solutions and expanding their market presence through partnerships with healthcare institutions.

However, the market also faces limitations such as high costs associated with advanced diagnostic tools, regulatory challenges, and the need for skilled personnel to operate complex equipment. Additionally, the threat of emerging and re-emerging infectious diseases poses continuous challenges to keeping diagnostic methods up-to-date.

Areas for innovation and research include the development of point-of-care diagnostics that provide immediate results, enhancing the utility of diagnostics in remote or resource-limited settings. Research into multiplex diagnostics, which can simultaneously test for multiple pathogens, offers another avenue for streamlined and cost-effective solutions. The market remains dynamic, with a focus on evolving technologies and the need for continual adaptation to emerging infectious threats, which underscores the critical role of strategic innovation for sustained business growth.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Healthcare-associated Infectious Disease Diagnostics Market

The Healthcare-associated Infectious Disease Diagnostics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Shift in focus from centralized laboratories to decentralized point-of-care testing
  • Growth in funding for research on infectious disease diagnostics
• Market Restraints
  • Stringent regulations to prevent HAIs in healthcare settings
  • Sophisticated mechanisms available to control HAIs
• Market Opportunities
  • Increase in target patients with healthcare-associated infections
  • High growth potential in low and middle-income countries
  • Growing penetration of POC tests to diagnose HAIs
• Market Challenges
  • Inadequate reimbursements
  • Low prevalence of HAIs in high-income nations

Porter's Five Forces: A Strategic Tool for Navigating the Healthcare-associated Infectious Disease Diagnostics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Healthcare-associated Infectious Disease Diagnostics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Healthcare-associated Infectious Disease Diagnostics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Healthcare-associated Infectious Disease Diagnostics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Healthcare-associated Infectious Disease Diagnostics Market

A detailed market share analysis in the Healthcare-associated Infectious Disease Diagnostics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Healthcare-associated Infectious Disease Diagnostics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Healthcare-associated Infectious Disease Diagnostics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Healthcare-associated Infectious Disease Diagnostics Market

A strategic analysis of the Healthcare-associated Infectious Disease Diagnostics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Healthcare-associated Infectious Disease Diagnostics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., Biomerieux SA, Co-Diagnostics Inc., Danaher Corporation, DiaSorin S.p.A., DNAe Group Holdings Ltd, GNA Biosolutions GmbH, Meridian Bioscience Inc. by SD Biosensor, Qiagen N.V., Quidel Corporation, Roche Holding AG, Siemens Healthineers AG, and Thermo Fisher Scientific Inc..

Market Segmentation & Coverage

This research report categorizes the Healthcare-associated Infectious Disease Diagnostics Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Product & Service, market is studied across Assays, Kits & Reagents, Instruments, and Services & Software.
• Based on Disease Type, market is studied across Chlamydia Trachomatis Genital Infection & Gonorrhea, Hepatitis, Hospital-Acquired Infections, Human Immunodeficiency Virus, Human Papillomavirus, Influenza, and Tuberculosis.
• Based on End-user, market is studied across Academic & Research Institutes, Hospital & Clinical Laboratories, Physician Offices, and Reference Laboratories.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Shift in focus from centralized laboratories to decentralized point-of-care testing
    • 5.1.1.2. Growth in funding for research on infectious disease diagnostics
  • 5.1.2. Restraints
    • 5.1.2.1. Stringent regulations to prevent HAIs in healthcare settings
    • 5.1.2.2. Sophisticated mechanisms available to control HAIs
  • 5.1.3. Opportunities
    • 5.1.3.1. Increase in target patients with healthcare-associated infections
    • 5.1.3.2. High growth potential in low and middle-income countries
    • 5.1.3.3. Growing penetration of POC tests to diagnose HAIs
  • 5.1.4. Challenges
    • 5.1.4.1. Inadequate reimbursements
    • 5.1.4.2. Low prevalence of HAIs in high-income nations
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Healthcare-associated Infectious Disease Diagnostics Market, by Product & Service

• 6.1. Introduction
• 6.2. Assays, Kits & Reagents
• 6.3. Instruments
• 6.4. Services & Software

7. Healthcare-associated Infectious Disease Diagnostics Market, by Disease Type

• 7.1. Introduction
• 7.2. Chlamydia Trachomatis Genital Infection & Gonorrhea
• 7.3. Hepatitis
• 7.4. Hospital-Acquired Infections
• 7.5. Human Immunodeficiency Virus
• 7.6. Human Papillomavirus
• 7.7. Influenza
• 7.8. Tuberculosis

8. Healthcare-associated Infectious Disease Diagnostics Market, by End-user

• 8.1. Introduction
• 8.2. Academic & Research Institutes
• 8.3. Hospital & Clinical Laboratories
• 8.4. Physician Offices
• 8.5. Reference Laboratories

9. Americas Healthcare-associated Infectious Disease Diagnostics Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Healthcare-associated Infectious Disease Diagnostics Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Healthcare-associated Infectious Disease Diagnostics Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Abbott Laboratories
• 2. Becton, Dickinson and Company
• 3. Bio-Rad Laboratories, Inc.
• 4. Biomerieux SA
• 5. Co-Diagnostics Inc.
• 6. Danaher Corporation
• 7. DiaSorin S.p.A.
• 8. DNAe Group Holdings Ltd
• 9. GNA Biosolutions GmbH
• 10. Meridian Bioscience Inc. by SD Biosensor
• 11. Qiagen N.V.
• 12. Quidel Corporation
• 13. Roche Holding AG
• 14. Siemens Healthineers AG
• 15. Thermo Fisher Scientific Inc.